Mario Saltarelli M.D. Ph.D. has more than 20 years of leadership experience in the biopharmaceutical sector, where he has focused on the identification, growth, and advancement of therapeutics development pipelines through the application of advanced translational paradigms. Dr. Saltarelli currently serves as Chief Medical Officer of Entrada Therapeutics in Boston. Previously, he served as Chief Medical Officer of Syntimmune, a mid-stage biopharmaceutical company focused on the development of therapeutics for rare autoimmune diseases, which was acquired by Alexion Pharmaceuticals in November 2018. Prior to Syntimmune, Dr. Saltarelli served as senior vice president and head of early development and neurology at Vertex Pharmaceuticals. At Vertex, he led the company’s early development activities, including translational medicine, clinical pharmacology, clinical biomarkers and neurology.